• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Single institution prescribing pattern of finerenone in patients with type 2 diabetes and/or chronic kidney disease in the USA.

作者信息

Zhang Rong M

机构信息

Division of Endocrinology, Metabolism, and Lipid Research, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.

出版信息

Clin Kidney J. 2023 Apr 5;16(9):1538-1539. doi: 10.1093/ckj/sfad073. eCollection 2023 Sep.

DOI:10.1093/ckj/sfad073
PMID:37664579
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10469089/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b5/10469089/1e8384860ec7/sfad073fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b5/10469089/1e8384860ec7/sfad073fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99b5/10469089/1e8384860ec7/sfad073fig1.jpg

相似文献

1
Single institution prescribing pattern of finerenone in patients with type 2 diabetes and/or chronic kidney disease in the USA.美国单机构中2型糖尿病和/或慢性肾脏病患者非奈利酮的处方模式
Clin Kidney J. 2023 Apr 5;16(9):1538-1539. doi: 10.1093/ckj/sfad073. eCollection 2023 Sep.
2
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.在 2 型糖尿病合并慢性肾脏病患者中，用非奈利酮治疗的心血管和肾脏结局：FIDELITY 汇总分析。
Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777.
3
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.非奈利酮在慢性肾脏病和糖尿病患者中的肾脏功能/蛋白尿与心衰结局。
JACC Heart Fail. 2022 Nov;10(11):860-870. doi: 10.1016/j.jchf.2022.07.013. Epub 2022 Oct 12.
4
Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.在患有 2 型糖尿病和慢性肾病的患者中，使用非奈利酮与治疗后肺炎和 COVID-19 不良事件减少相关：FIDELITY 汇总二次分析。
JAMA Netw Open. 2022 Oct 3;5(10):e2236123. doi: 10.1001/jamanetworkopen.2022.36123.
5
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.非奈利酮可降低慢性肾脏病合并 2 型糖尿病患者的新发心房颤动风险。
J Am Coll Cardiol. 2021 Jul 13;78(2):142-152. doi: 10.1016/j.jacc.2021.04.079. Epub 2021 May 17.
6
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.非奈利酮与慢性肾脏病合并 2 型糖尿病患者的心血管结局。
Circulation. 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16.
7
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.FIDELITY研究的一项预先设定的探索性分析，考察了非奈利酮在慢性肾脏病合并2型糖尿病患者中的使用情况及肾脏结局。
Kidney Int. 2023 Jan;103(1):196-206. doi: 10.1016/j.kint.2022.08.040. Epub 2022 Oct 28.
8
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.在 2 型糖尿病合并慢性肾脏病患者中用非奈利酮治疗血压和心肾结局。
Hypertension. 2022 Dec;79(12):2685-2695. doi: 10.1161/HYPERTENSIONAHA.122.19744. Epub 2022 Oct 12.
9
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.在接受 GLP-1RA 治疗的慢性肾脏病和 2 型糖尿病患者中，非奈利酮的疗效和安全性：来自 FIDELIO-DKD 试验的亚组分析。
Diabetes Obes Metab. 2022 Jan;24(1):125-134. doi: 10.1111/dom.14558. Epub 2021 Oct 11.
10
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.依基线糖化血红蛋白和胰岛素使用情况评估慢性肾脏病和 2 型糖尿病患者的非奈利酮治疗效果：来自 FIDELIO-DKD 研究的分析。
Diabetes Care. 2022 Apr 1;45(4):888-897. doi: 10.2337/dc21-1944.

引用本文的文献

1
Diabetes Educators: Understanding the Role of Finerenone in Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.糖尿病教育工作者：了解非奈利酮在2型糖尿病相关慢性肾脏病中的作用
Diabetes Ther. 2025 May;16(5):763-784. doi: 10.1007/s13300-025-01705-y. Epub 2025 Mar 4.
2
The Role of Finerenone in Optimizing Cardiovascular-Kidney-Metabolic Health: Everything PCPs Should Know.非奈利酮在优化心血管-肾脏-代谢健康中的作用：基层医疗医生应知晓的一切。
Fed Pract. 2024 Nov;41(Suppl 6):S41-S46. doi: 10.12788/fp.0535. Epub 2024 Nov 20.
3
Population Health Management and Guideline-Concordant Care in CKD: A Secondary Analysis of Kidney Coordinated HeAlth Management Partnership.

本文引用的文献

1
Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.非奈利酮：用于治疗 2 型糖尿病相关慢性肾脏病的盐皮质激素受体拮抗剂。
Expert Rev Clin Pharmacol. 2022 May;15(5):501-513. doi: 10.1080/17512433.2022.2094770. Epub 2022 Jul 3.
慢性肾脏病中的人群健康管理与指南一致性照护：肾脏协调健康管理伙伴关系的二次分析
J Am Soc Nephrol. 2025 May 1;36(5):869-881. doi: 10.1681/ASN.0000000544. Epub 2024 Nov 1.
4
Finerenone: Who should prescribe it for CKD? The physician associate's perspective.非奈利酮：谁应为慢性肾脏病患者开具此药？医师助理的观点。
J Nephrol. 2024 Nov;37(8):2161-2170. doi: 10.1007/s40620-024-02015-5. Epub 2024 Jul 3.